| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2,6-Dibromopyridine does not have a defined pharmacological target of its own, as it is a synthetic intermediate. It is used as a pharmaceutical intermediate in the synthesis of the migraine drug Lasmiditan. Lasmiditan is an oral prescription drug used to treat acute migraine headaches with or without aura. The compound is also used as a starting material to synthesize 2,2'-bipyridines via Stille-type cross-coupling reactions.
|
|---|---|
| ln Vitro |
In vitro, 2,6-dibromopyridine is primarily used as a chemical reagent and synthetic intermediate. It is used as a pharmaceutical intermediate in the synthesis of Lasmiditan and as a starting material to synthesize 2,2'-bipyridines via Stille-type cross-coupling reactions. As a dibrominated pyridine, it is a valuable building block for cross-coupling reactions and for the synthesis of various organic compounds.
|
| ln Vivo |
In vivo activity data for 2,6-dibromopyridine itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of Lasmiditan and other drug candidates that are subsequently evaluated in animal models and clinical settings. The compound's in vivo relevance is indirect, through the biological activities of the final pharmaceutical compounds derived from its pyridine scaffold.
|
| Enzyme Assay |
For in vitro chemical synthesis, 2,6-dibromopyridine is used as a building block for the preparation of various compounds. The bromine atoms at the 2 and 6 positions provide handles for selective cross-coupling reactions such as Stille couplings and Suzuki-Miyaura couplings. The compound can be used to synthesize 2,2'-bipyridines and other functionalized pyridines. Standard protocols involve reacting the compound with appropriate reagents under controlled conditions.
|
| Cell Assay |
For in vitro cell-based experiments, 2,6-dibromopyridine is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium.
|
| Animal Protocol |
In vivo animal studies using 2,6-dibromopyridine are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For Lasmiditan and other pharmaceutical candidates derived from this building block, efficacy studies would typically be performed in mouse models of migraine or other relevant diseases. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,6-dibromopyridine as a standalone compound are not characterized in the literature. The compound has a molecular weight of 236.89 g/mol, which may limit oral bioavailability. The bromine atoms may influence metabolic stability and lipophilicity. The pyridine nitrogen may be subject to N-oxidation. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
2,6-Dibromopyridine is a research chemical and should be handled with appropriate laboratory safety precautions. As a brominated compound, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| References | |
| Additional Infomation |
2,6-Dibromopyridine (CAS 626-05-1) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a pharmaceutical intermediate in the synthesis of the migraine drug Lasmiditan and as a starting material for the synthesis of 2,2'-bipyridines. No clinical trials or approved therapeutic indications exist for this compound itself.
|
| Molecular Formula |
C5H3BR2N
|
|---|---|
| Molecular Weight |
236.89
|
| Exact Mass |
234.863
|
| CAS # |
626-05-1
|
| PubChem CID |
12274
|
| Appearance |
White to off-white solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
255.9±20.0 °C at 760 mmHg
|
| Melting Point |
117-119 °C(lit.)
|
| Flash Point |
108.5±21.8 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.607
|
| LogP |
2.29
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
68.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C([H])=C([H])C([H])=C(N=1)Br
|
| InChi Key |
FEYDZHNIIMENOB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H3Br2N/c6-4-2-1-3-5(7)8-4/h1-3H
|
| Chemical Name |
2,6-dibromopyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~422.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2214 mL | 21.1068 mL | 42.2137 mL | |
| 5 mM | 0.8443 mL | 4.2214 mL | 8.4427 mL | |
| 10 mM | 0.4221 mL | 2.1107 mL | 4.2214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
